Path ID: DB00110_MESH_D018357_1
Concepts
| Identifier | Name | Type |
|---|---|---|
| MESH:D000069455 | palivizumab | Drug |
| UniProt:P13843 | Fusion glycoprotein F0 | Protein |
| GO:0019064 | fusion of virus membrane with host plasma membrane | BiologicalProcess |
| GO:0046718 | viral entry into host cell | BiologicalProcess |
| taxonomy:12814 | Respiratory syncytial virus | OrganismTaxon |
| MESH:D018357 | Respiratory syncytial virus infection | Disease |
Relationships
NOTE: predicates are annotated in Biolink Model (v1.3.0)
| Subject | Predicate | Object |
|---|---|---|
| Palivizumab | NEGATIVELY REGULATES | Fusion Glycoprotein F0 |
| Fusion Glycoprotein F0 | POSITIVELY REGULATES | Fusion Of Virus Membrane With Host Plasma Membrane |
| Fusion Glycoprotein F0 | POSITIVELY REGULATES | Viral Entry Into Host Cell |
| Viral Entry Into Host Cell | IN TAXON | Respiratory Syncytial Virus |
| Fusion Of Virus Membrane With Host Plasma Membrane | IN TAXON | Respiratory Syncytial Virus |
| Respiratory Syncytial Virus | CAUSES | Respiratory Syncytial Virus Infection |
Comment: This drug seems to be used for prophylaxis only because of its high cost and limited efficacy (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7096974/#CR20). It’s believed to elicit an antibody-dependent cell-mediated cytotoxicity activity in vivo ()https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4000855/.
Reference: